

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Type or print name of person signing certification

Signature

Date

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant:	Darcey Clark	Group Art Unit:	4173
Serial No.:	10/572,543	Examiner:	STONE, Christopher R.
Filing Date:	November 28, 2006	Conf. No.:	7392
For:	Use of Chk1 Inhibitors to Control Cell Proliferation		
Docket No.:	X-17671		

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Sir:

This response addresses the Office communication provided on December 10, 2007 wherein the present application was subjected to a restriction requirement.

Applicants make provisional elections, with traverse, submit the following remarks, and request reconsideration of this requirement for the present application.

Applicants are required under 37 CFR § 1.143 to make a provisional election. Applicants respectfully note that no groups are provided by the Office in the present Office communication. Applicants provisionally elect, with traverse, gemcitabine for the Chk1 activator, Compound 281 (identified as (1-[5-methyl-2-(3-piperidin-1-yl-propoxy)-phenyl]-3-(5-methyl-pyrazin-2-yl)-urea as provided on page 145 of WO02070494 and corresponding to the claimed variable groups in which X1 and X2 are N(R1)- wherein R1 is hydro, Y is O, W is heteroaryl substituted with R5 wherein R5 is methyl, and Z is aryl substituted with R2 wherein R2 is methyl and OR3 and R3 is C1-3alkyleneC3-8heterocycloalkyl) for the Chk1 inhibitor, and non-small cell lung cancers as the cancer species in order to comply with 37 CFR § 1.143 and to facilitate the Office's search. The provisional elections encompass claims 69 through 71 and 73.